| 000 | 03804nam a22004815i 4500 | ||
|---|---|---|---|
| 001 | vtls000559708 | ||
| 003 | RU-ToGU | ||
| 005 | 20210922090021.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 170212s2015 gw | s |||| 0|eng d | ||
| 020 |
_a9783319179728 _9978-3-319-17972-8 |
||
| 024 | 7 |
_a10.1007/978-3-319-17972-8 _2doi |
|
| 035 | _ato000559708 | ||
| 040 |
_aSpringer _cSpringer _dRU-ToGU |
||
| 050 | 4 | _aRC261-271 | |
| 072 | 7 |
_aMJCL _2bicssc |
|
| 072 | 7 |
_aMED062000 _2bisacsh |
|
| 082 | 0 | 4 |
_a614.5999 _223 |
| 245 | 1 | 0 |
_aResistance to Aromatase Inhibitors in Breast Cancer _helectronic resource _cedited by Alexey Larionov. |
| 260 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2015. |
||
| 300 |
_aXVI, 288 p. 56 illus., 27 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 490 | 1 |
_aResistance to Targeted Anti-Cancer Therapeutics, _x2196-5501 ; _v8 |
|
| 520 | _aThe book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents). A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors’ team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors. | ||
| 650 | 0 |
_amedicine. _9566220 |
|
| 650 | 0 |
_aCancer Research. _9566267 |
|
| 650 | 0 |
_aDrug Resistance. _9329106 |
|
| 650 | 0 |
_aMolecular biology. _9566793 |
|
| 650 | 1 | 4 |
_aBiomedicine. _9566246 |
| 650 | 2 | 4 |
_aCancer Research. _9566267 |
| 650 | 2 | 4 |
_aDrug Resistance. _9329106 |
| 650 | 2 | 4 |
_aMolecular Medicine. _9303561 |
| 700 | 1 |
_aLarionov, Alexey. _eeditor. _9466416 |
|
| 710 | 2 |
_aSpringerLink (Online service) _9143950 |
|
| 773 | 0 | _tSpringer eBooks | |
| 830 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics, _9414060 |
|
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-319-17972-8 |
| 912 | _aZDB-2-SBL | ||
| 999 | _c414527 | ||